TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Novo Nordisk Shares Surge 7% In Tuesday Pre-Market After US FDA Approves Wegovy Pill

Benzinga Logo Benzinga By Namrata Sen
Novo Nordisk Shares Surge 7% In Tuesday Pre-Market After US FDA Approves Wegovy Pill

Novo Nordisk's stock surged 7.36% in pre-market trading following FDA approval of Wegovy pill, the first GLP-1 oral medication approved globally. The pill will be available starting early January at $149/month. Despite this win, Novo Nordisk has faced challenges this year including supply chain issues, disappointing trial results, and downward guidance revisions, with year-to-date stock decline of 45.04%.

Insights
HPEpC   neutral

Participated in benchmark without standout performance highlights


NVO   positive

FDA approval of Wegovy pill is a significant milestone as the first global GLP-1 oral medication approval, driving 7.36% pre-market surge and positioning the company ahead of competitors in the weight-loss drug market.